Genmab raises its 2016 guidance

Thursday 3 November 2016
Country

Denmark

Genmab A/S has raised its guidance for 2016 while announcing strong nine-month revenue, raising expectations that its partnered anticancer drug, Darzalex (daratumumab), will generate serious income in the future. The drug has received two breakthrough designations from the FDA..